Newsletter Subject

4 Stocks to Watch Closely in Today's Session 👀

From

elitetrade.club

Email Address

adam@elitetrade.club

Sent On

Fri, Sep 23, 2022 11:58 AM

Email Preheader Text

Biotech is leading today's premarket gainers. Get a full report on all 4 top stocks inside Good Morn

Biotech is leading today's premarket gainers. Get a full report on all 4 top stocks inside [Image](www.elitetrade.club) Good Morning! Hey, guys and gals. It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Happy Friday! It's September 23rd. Let's get ready to trade! Markets 📈 The Nasdaq sold-off for 1.4% in a down day for US markets on Thursday. The S&P 500 lost 0.8%, and the Dow slid to a 0.4% decline. The small-cap Russell 2K tumbled 2.3% in the trading session. Today, futures are pointing to another down open for US benchmarks. S&P 500 contracts are currently showing a 1.4% loss in early morning trading. Sponsored [The A.I. That Every Trader Should Use]( 🤖 There's nothing wrong with the diligent analysis you're doing. That's a huge reason why you've been successful so far, but that's not enough. Unfortunately, you'll never fully take control of your financial future if you're only using information from the past, such as lagging indicators and historical data. To bring your trading success to new heights, you will need a tool that uses past data to predict future stock movements. [Click here to see this AI forecasting technology at work.]( Premarket Highlights 🔎 - The British pound tumbled to a 37-year low this morning on news of a larger-than-expected tax cut financed and increased government borrowing. - Chinese auditors are starting to face US inspections from the Public Company Accounting Oversight board. Inspectors will decide if firms like Alibaba [BABA], Yum China [YUMC], and others can keep their US listings. What to Watch Today 👀 Reality Sets In Investors are coming to grips with the fact that the Federal Reserve is going to see its rate-hike plan all the way through, and markets have been in the red for most of the week as a result. However, the market is still in denial about the likelihood of a US recession, which seems all but inevitable at this point. Point being, don't fool yourself into thinking we are anywhere near the bottom of this bear market. International 🌍 Asia Hong Kong's Hang Seng lost 1.2% overnight, while the Aussie ASX 200 fell 1.9%. The Shanghai Composite slid to a 0.7% loss. Europe Europe is in the midst of an ugly selloff. The German DAX is down 2.7%, and France's CAC 40 is showing a 2.4% loss. Italy's FTSE MIB tumbled to a 3.2% loss, and the Euro Stoxx 600 is down 2.8%. Major Earnings 💰 Huize [HUIZ] ... AM InMed Pharmaceuticals [INM] ... AM Economy 🏗 - S&P U.S. manufacturing PMI (flash) [Sep] ... 9:45a - S&P U.S. services PMI (flash) [Sep] ... 9:45a Running Hot 🔥 Gainers - Nextplat Corp [NXPL] >> +29.6% - Moleculin Biotech [MBRX] >> +22.9% - T2 Biosystems [TTOO] >> +17.7% Decliners - Spectrum [SPPI] >> (21.4%) - Splash Beverage [SBEV] >> (26.8%) - Neptune Wellness Solutions [NEPT] >> (14.5%) Dentsply Sirona [XRAY] - Last Close: $29.55 News of a personnel change is lifting Densply Sirona this morning. The dental equipment manufacturer announced after yesterday's closing bell that it had appointed a new Chief Financial Officer. The company recruited Integra Lifesciences COO Glenn Coleman to take the helm as CFO, and he'll start his new position on Sept. 26th. Coleman will replace interim CFO Barbara Bodem. XRAY is leading the S&P 500 with a 3.0% premarket gain. My Take: CFO is an important position, so investors were pleased to see the firm find someone to take the role on a permanent basis. However, I don't think it really changes the stock's long-term outlook. Sellas Life Sciences Group [SLS] - Last Close: $2.31 Sellas Life Sciences says it will provide a key drug update at an upcoming conference. The late-stage clinical biotech firm said this morning that it will host a poster presentation related to its CDK9 inhibitor, GFH009, at the upcoming Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO). Sellas will make its presentation on Wednesday, Sept. 28th, at 6:05 p.m., with Senior VP of Clinical Development Dragan Cicic serving as host. According to a company press release, the poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0. Shares of SLS are up 24.2% in today's premarket. My Take: It sounds like SLS is getting ready to unveil some positive data at this conference next week, and investors are positioning themselves in anticipation of the potential rally catalyst. However, it's anyone's guess whether the presentation will live up to this early hype, so don't get tricked into over-paying if you decide to get in this one. Sonendo Inc [SONX] - Last Close: $0.9071 Sonendo is making a big push higher after an early-morning announcement. The commercial-stage medical technology company unveiled a $63 million private placement in today's pre-bell trading session. New and existing investors, including Pura Vida Investments, First Light Asset Management, Blue Water Life Science Advisors, and others participated in the private placement financing. CEO Bjarne Bergheim said the new capital will shore up its balance sheet and product development. SONX is one of this morning's top performers with a 66.5% gain. My Take: Investors obviously like this deal for SONX. The company must be doing something right if it convinced so many of its backers to pony up more cash. This small-float stock could be worth your attention. Ruby Therapeutics [RUBY] - Last Close: $0.4546 Ruby Therapetics is enjoying a sharp rebound rally today. The biopharma firm has struggled since pulling the plug on two key cancer trials last week, but it's showing signs of life ahead of today's open. RUBY set a new 52-week low on Thursday, but the stock is bouncing back with sharp gains today. Earlier in the week, Ruby Therapeutics announced its CEO Pablo J. Cagnoni, M.D. will host a "fireside chat" at Guggenheim Nantucket Therapeutics Conference on Tuesday, according to a company press release. RUBY is one of today's most active premarket stocks, and it's up 30.7%. My Take: It's unclear what will be discussed at the so-called "fireside chat," but the event could be a catalyst for this beaten down stock. RUBY's decision to cancel its cancer trials really hurt investor sentiment, but it's possible the resultant declines have been overdone at this point. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 or [click here]( to sign up now and get our watchlists sent directly to your phone! Or Text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](

Marketing emails from elitetrade.club

View More
Sent On

29/11/2022

Sent On

28/11/2022

Sent On

28/11/2022

Sent On

26/11/2022

Sent On

25/11/2022

Sent On

25/11/2022

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2022 SimilarMail.